Your Notifications
All done, no notifications

What is Myelodysplastic syndrome (MDS)?

Myelodysplastic syndrome is a group of cancers that prevents hematopoietic stem cells from developing into healthy blood cells. Without enough healthy blood cells, people risk developing dangerous illnesses such as anemia, frequent infections, and uncontrollable bleeding. Some patients with MDS may develop acute myeloid leukaemia (AML).

What is the Importance of Timely Treatment?

Myelodysplastic Syndrome (MDS) should be treated as soon as possible to prevent it from progressing to acute myeloid leukaemia (AML), relieve symptoms such as fatigue and anaemia, and improve general health. Early intervention enhances the efficacy of chemotherapy and stem cell transplants, improving outcomes. It also helps to reduce life-threatening complications such as infections and bleeding, which improves the prognosis and survival rates. Therefore, timely treatment is critical for effectively controlling MDS and giving patients a better long-term outlook.

What are the Common Symptoms of Myelodysplastic syndromes (MDS)?

People with myelodysplastic syndromes may not exhibit signs and symptoms at first.

Myelodysplastic syndromes could cause:

  • Fatigue
  • Shortness of breath.
  • Unusual paleness (pallor) caused by decreased red blood cell count (anaemia)
  • Low blood platelet count (thrombocytopenia) causes easy or uncommon bruising and bleeding.
  • Pinpoint-sized red spots beneath the skin caused by bleeding.
  • Frequent infections caused by a low white blood cell count (leukopenia).

Types of Myelodysplastic syndrome (MDS)

The World Health Organization classifies myelodysplastic syndromes into subcategories based on the kind of blood cells involved (red cells, white cells, and platelets).

The myelodysplastic syndrome has several subtypes, including:

  • Myelodysplastic disorders with a single lineage dysplasia: One type of blood cell, such as white blood cells, red blood cells, or platelets, has a low number and appears abnormal under the microscope.
  • Myelodysplastic disorders with multilineage dysplasia: This subtype has two or three aberrant blood cell types.
  • Myelodysplastic syndromes with ring sideroblasts: This subtype includes a small number of one or more blood cell types. One distinguishing aspect is the presence of extra iron rings in existing red blood cells in the bone marrow.
  • Myelodysplastic syndromes with a solitary del(5q) chromosomal defect: People with this subtype have low red blood cells, which contain a unique mutation in their DNA.
  • Myelodysplastic diseases with excessive blasts: In this subtype, any of the three types of blood cells, red blood cells, white blood cells, or platelets, may be depleted and appear abnormal under the microscope. The blood and bone marrow contain very young blood cells known as blasts.
  • Myelodysplastic disorders that cannot be classified: This subtype has a lower amount of one or more types of mature blood cells, and the cells may appear unusual under a microscope. Sometimes, blood cells appear normal, but investigation may reveal DNA alterations linked with myelodysplastic syndromes.

Causes, Risk Factors and Complications of Myelodysplastic syndromes (MDS)

Causes

  • A healthy person's bone marrow produces new, immature blood cells that mature over time. Myelodysplastic disorders occur when this process is disrupted, preventing the blood cells from maturing.
  • Rather than growing properly, blood cells die in the bone marrow or shortly after entering the bloodstream. Over time, there are more immature, defective cells than healthy ones, resulting in issues such as fatigue caused by a lack of healthy red blood cells (anaemia), infections caused by a lack of healthy white blood cells (leukopenia), and bleeding caused by a lack of blood-clotting platelets.
  • The majority of myelodysplastic syndromes have no known causes. Others are caused by exposure to cancer treatments like chemotherapy and radiation.

Risk Factors

The following factors can raise your risk of myelodysplastic syndromes:

  • Older age: Myelodysplastic disorders primarily affect adults over the age of 60.
  • Previously treated with chemotherapy or radiation: Chemotherapy and radiation therapy, two frequent cancer treatments, can raise your chance of developing myelodysplastic syndromes.
  • Exposure to specific chemicals

Complications

Myelodysplastic syndromes can have the following complications:

  • Anaemia: Anemia, or a lack of red blood cells, can cause fatigue.
  • Recurrent infections: A low white blood cell count raises your risk of serious illnesses.
  • Bleeding that won't stop: Excessive bleeding might occur when you do not have enough platelets in your blood to stop it.
  • Increased risk of cancer: Some persons with myelodysplastic syndromes may develop malignancy of the bone marrow and blood cells (leukaemia).

Connect with our advisor for a PRIORITY response

Latest Research and Technologies in the Treatment of Myelodysplastic syndromes (MDS) in India

  • Recent research in India has focused on targeted treatments, immunotherapy, and gene editing to treat MDS better. Innovations in stem cell transplants, next-generation sequencing for better diagnostics, and novel medications are all increasing patient outcomes. Clinical trials are under underway at major hospitals to investigate these advanced treatments.

Myelodysplastic syndromes (MDS) Prevention Tips

  • While there is no sure approach to prevent Myelodysplastic Syndromes (MDS), the following steps may help lessen the risk or contribute to early detection:
  • Prevent exposure to hazardous chemicals.
  • Minimise radiation exposure.
  • Maintain a healthy lifestyle by eating balanced food, exercising regularly, and not smoking.
  • Monitor genetic disorders that may raise the risk of MDS.
  • Regular check-ups and blood testing are recommended for early detection, particularly for those with a family history or an increased risk.

Treatment options for Myelodysplastic syndromes (MDS)

Chemotherapy: Healthcare practitioners may administer the same chemotherapy used to treat AML. It uses medications to eliminate cancer cells and inhibit tumour growth.


Cost Start From USD 600 - USD 700Explore Options

Immunosuppressive therapy: Providers may utilise this medication for some MDS subtypes. Immunosuppressive medication reduces overactive immune systems, reducing the need for transfusions.


Cost Start From USD 3000 - USD 5000Explore Options

Bone Marrow Transplant: A bone marrow transplant, also known as a stem cell transplant, is the only treatment that can cure myelodysplastic disorders.


Cost Start From USD 25000 - USD 35000Explore Options

  • Complete blood count (CBC) with differential: Your doctor will take blood samples to study your red and white blood cells, including measuring the quantity of each white blood cell type.
  • Peripheral blood smear: Doctors will examine your blood sample to see if there are any changes in the amount, type, shape, or size of blood cells, as well as whether you have too much iron in your red blood cells.
  • Cytogenetic analysis: A medical pathologist examines a blood sample under a microscope to search for changes in your blood cell's chromosomes.
  • Bone marrow biopsy: In this process, your doctor inserts a hollow needle into your hipbone to extract bone marrow, blood, and a small piece of bone for examination under a microscope.

Rehabilitation for Hepatocellular Carcinoma (HCC) is an essential component of the rehabilitation process and enhancing quality of life, particularly following surgery, liver transplantation, or other treatments. Here are some essential rehabilitation choices for HCC patients:

  • Physical rehabilitation: Tailored exercise routines, which include light cardio and strength-building exercises, can assist in improving overall health, increasing stamina, and reducing tiredness after treatment.
  • Managing malnutrition: Nutritional advice can help with these concerns, including the use of supplements or intravenous feeding if necessary.
  • Psychosocial support: Therapy or joining support groups can help cancer patients cope with the emotional and mental problems of their treatment.

MediGence can assist and guide you in selecting the best physician and medical facility for your care.

Treatment for myelodysplastic syndromes may include medications such as:

  • Increase the number of blood cells your body produces.
  • Stimulate blood cells to develop.
  • Suppress your immune system.
  • Help persons with a specific genetic abnormality.
  • Treat infections.

Instantly Connect with our Specialists

Doctor 1
Doctor 2
Doctor 3
Doctor 4
Doctor 5
Doctor 6
Doctor 7
Doctor 8

Hospitals for Myelodysplastic syndromes (MDS) in India

Artemis Health Institute: Top Doctors, and Reviews
Artemis Health Institute

Gurgaon, India

Artemis Hospital, established in 2007 in Gurgaon, India, is a 750+ bed, state-of-the-art multi-speciality hospital and the first in Gurgaon accredited by JCI and NABH. A flagship of the Apollo Tyres Group, it offers advanced care across cardiology, oncology, orthopaedics, neurology, and transplant medicine, supported by modern infrastructure and 60+ world-class operating theatres. Its Centres of Excellence span critical areas like heart, cancer, neurosciences, orthopaedics, and women & child care. Guided by values of Service, Compassion, and Integrity, Artemis combines innovation, technology, and affordability, making it a trusted international healthcare destination for comprehensive and compassionate patient care.

Apollo Hospitals: Top Doctors, and Reviews
Apollo Hospitals

Hyderabad, India

Apollo Hospitals located in Hyderabad, India is accredited by JCI, NABH. Also listed below are some of the most prominent infrastructural details:

  • A premier multi-specialty hospital with 477-bed capacity
  • More than 50 specialties, super-specialties
  • 12 Centers of Excellence
  • The Institutes for Heart Diseases, Neurosciences, Cancer, Emergency, Orthopaedics, Renal Diseases, and Transplants
  • Centers of Excellence are known for patient care, training and research
  • Doctors with years of truly global experience in healthcare delivery
Star Hospitals: Top Doctors, and Reviews
Star Hospitals

Hyderabad, India

Star Hospitals located in Hyderabad, India is accredited by NABH, NABL. Also listed below are some of the most prominent infrastructural details:

  • The bed capacity of Star Hospitals, Hyderabad, India is 130.
  • The hospital has Intensive Care Units which are upgraded with the latest technologies.
  • International patient care services are applied to make the process of medical travel easier for international patients.
  • Centres of Excellence across disciplines such as Cardiac Sciences, Renal Sciences, Critical Care, ENT, Spine Surgery etc.
  • A radiology centre which has been digitised.
  • There are Centers of Excellence for prominent specialties such as cardiac care and neurosciences, there are a total of six.

Our Services to better your experience

Opinion & Option

We submit the most accurate opinion and options from one or more countries for your review

Consult Privately

Consult with a certified specialist privately on our telemedicine platform even before you decide to travel

Logistics

We handle flights, visas, transfers, and accommodation—so you can focus on your health.

Recovery

Our In-house rehabilitation service packages to better your recovery and treatment outcome

Why Choose India for Myelodysplastic Syndromes (MDS) Treatment?

Here are some of the reasons for choosing India:

  • Due to advancements in medical facilities, such as minimally invasive surgical techniques.
  • World-class experts include highly experienced doctors, JCI, and NABH-accredited healthcare institutions.
  • Compared to other countries, treatment in Indian hospitals is cost-effective.
  • Indian hospitals provide International patient services, including a multilingual support system.
  • Improved treatment methods and biological therapies

Frequently Asked Questions

MDS patients' life expectancy varies according to their subtype, overall health, and response to treatment. Patients with low-risk MDS can live for many years, whereas those with high-risk MDS may develop acute leukaemia, lowering life expectancy. Regular monitoring and treatment can lead to better outcomes.

MDS and leukaemia involve the bone marrow and blood cells, but MDS is a disorder in which the bone marrow generates abnormal cells. In contrast, leukaemia is characterised by the fast, uncontrolled proliferation of defective blood cells. MDS is sometimes thought to be a precursor to leukaemia since it can progress to acute myeloid leukaemia (AML) in some circumstances; however, the two illnesses are separate.

While most cases of MDS are not inherited, specific gene changes can raise the chance of getting the disease. In rare situations, MDS can be inherited as part of a genetic condition, such as Fanconi anaemia. You should speak with a genetic counsellor if you have a family history of blood diseases.

Yes, MDS is treatable, but treatment efficacy is determined by several factors, including the patient's age, overall health, and MDS subtype. Treatment aims to alleviate symptoms, boost blood cell counts, and prevent leukaemia from developing. In India, therapies include supportive care, chemotherapy, immunosuppressive therapy, and bone marrow/stem cell transplants.

Chemotherapy is commonly used to treat high-risk MDS or instances that develop to acute myeloid leukaemia. Chemotherapy medications kill abnormal cells in the bone marrow and restore normal blood cell production. In India, chemotherapy for MDS is provided in big cancer hospitals, where professionals personalise treatment plans.

Many MDS patients can lead very normal lives with proper care. However, symptoms such as exhaustion, recurrent infections, and the need for blood transfusions can influence one's life. Patients can typically retain a high quality of life by receiving therapies such as blood transfusions, medicines, and stem cell transplants.

India is conducting ongoing research and clinical trials to develop new medicines for MDS, such as innovative medications, immunotherapies, and targeted treatments. Some novel medicines aim to increase survival rates and lower the likelihood of MDS progressing to leukemia. Patients can discuss these alternatives with their doctor to learn about new treatments.